Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study
Authors 0
- Author list not loaded yet.
Cited by 1 stored of 20
1 result